Sanofi stock slips 0.80% to EUR 83.10 before Xetra open
Published on 11/20/2026 at 08:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSanofi enters DNA medicines deal
- Sanofi and Seawolf Therapeutics signed a research and exclusive licensing agreement for DNA-based treatments.
- The partnership could generate up to USD 1.2 billion in milestone payments for Seawolf, plus tiered royalties.
- The collaboration focuses initially on bleeding disorders and other undisclosed indications.
Sanofi stock traded at EUR 83.10 on Lang & Schwarz at 08:37:50 CET on Friday, November 20, 2026, 0.80 percent below the Xetra close of Thursday, November 19.
The pharmaceutical group is also in focus after agreeing a multi-target research partnership and exclusive licensing deal with Seawolf Therapeutics. The agreement covers DNA-based treatments for bleeding disorders and other undisclosed indications.
Deal expands Sanofi's pipeline
According to Pharmaceutical Technology, Seawolf could receive up to USD 1.2 billion in research, development and commercial milestone payments. The agreement also provides for tiered royalties on future sales of therapies developed through the collaboration.
The partnership gives Sanofi access to Seawolf's TRIDENT platform, which uses lipid nanoparticles to deliver DNA into cell nuclei. Seawolf is developing the approach for repeat dosing and longer-lasting therapeutic protein expression. The biotech is advancing programs in bleeding disorders and other disease areas while Sanofi adds another platform to its development pipeline.
Sanofi is a French pharmaceutical company with research and commercial operations across medicines and vaccines. The Seawolf agreement broadens its exposure to DNA-based drug development, although the milestone payments depend on research, development and commercial progress.
French equities trade within the broader CAC 40 market environment.
